Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nelipepimut-S Plus GM-CSF Vaccine

Known as: NeuVax Plus GM-CSF, Nelipepimut-S Plus Sargramostim, HLA A2/A3-Restricted HER-2/neu Peptide Vaccine Plus GM-CSF 
A cancer peptide vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (ERBB2) peptide from the extracellular domain of the… Expand
National Institutes of Health

Related topics

Related topics

1 relation
Antigen Sensitization

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing…
The development of HER2-targeted therapy has decreased recurrence rates and improved survival, transforming the natural history… Expand
Is this relevant?
2019
2019
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Purpose: In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2017
2017
Abstract OT3-01-04: VADIS trial: Phase II trial of the nelipepimut-S peptide vaccine in women with DCIS of the breast
Background: Our group has been investigating vaccination strategies in breast cancer. Specifically, we have been evaluating HER2… Expand
Is this relevant?
2016
2016
Adjuvant capesitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX…
1001Background: The role of capecitabine (X) in the adjuvant treatment of BC is not established, and few long-term survival data… Expand
Is this relevant?
2016
2016
The development and use of the E75 (HER2 369-377) peptide vaccine.
E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte… Expand
  • figure 1
Is this relevant?
2016
2016
A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice
Purpose: E75, a peptide derived from the Her2/neu protein, is the most clinically advanced vaccine approach against breast cancer… Expand
  • figure 1
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Abstract OT3-1-09: Combination immunotherapy with trastuzumab and the HER2 vaccine E75 (nelipepimut-S) in high-risk HER2+ breast cancer patients to prevent recurrence
Background: In an adjuvant phase II trial, the HER2-derived nelipepimut-S (E75) + GM-CSF vaccine (Neuvax) has been shown to… Expand
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
BACKGROUND E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Review
2014
Review
2014
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.
Nelipepimut-S (formerly known as E75) is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer… Expand
  • table 1
  • table 2
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2014
2014
Breast cancer: E75—a safe and effective vaccine for the prevention of disease recurrence
Breast cancer is the most common malignancy in women and even after curative treatment, approximately 10–20% of breast cancer… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE